Journal of the National Cancer Institute最新文献_第3页

Childbirth after cancer among 42,896 male adolescents and young adults: a population-based study 42,896名男性青少年和年轻人癌症后分娩：一项基于人群的研究

Journal of the National Cancer Institute Pub Date : 2025-01-02 DOI: 10.1093/jnci/djae347

Caitlin C Murphy, Jennifer S Wang, Andrea C Betts, Philip J Lupo, L Aubree Shay, Marlyn A Allicock, Caroline L Kirk, Sandi L Pruitt

{"title":"Childbirth after cancer among 42,896 male adolescents and young adults: a population-based study","authors":"Caitlin C Murphy, Jennifer S Wang, Andrea C Betts, Philip J Lupo, L Aubree Shay, Marlyn A Allicock, Caroline L Kirk, Sandi L Pruitt","doi":"10.1093/jnci/djae347","DOIUrl":"https://doi.org/10.1093/jnci/djae347","url":null,"abstract":"Background Few studies have examined childbirth and adverse perinatal outcomes among male adolescents and young adults with cancer (AYAs, diagnosed at age 15-39 years). We conducted a population-based assessment of these outcomes in a large, diverse sample. Methods Male AYAs diagnosed between January 1, 1995 and December 31, 2015 were identified using the Texas Cancer Registry and linked to live birth certificates and the Texas Birth Defects Registry through December 31, 2016. Cumulative incidence of live birth after diagnosis was estimated. Log binomial regression models were used to estimate prevalence of preterm birth (&lt;37 weeks), low birth weight (&lt;2,500 grams), small for gestational age (&lt;10th percentile), and any birth defect among liveborn offspring of male AYAs compared to age- and race/ethnicity-matched men without cancer. Results We identified 42,896 male AYAs, among whom germ cell cancers (20.0%) were the most common. There were 9,686 live births to 6,833 male AYAs after diagnosis. Cumulative incidence of live birth was 18.0% (95% CI 17.6, 18.4) at ten years after diagnosis. Ten-year cumulative incidence differed by cancer type (p &lt; .01) and was highest for thyroid (27.6%, 95% CI 25.4, 29.9) but lowest for gastrointestinal (9.6%, 95% CI 8.1, 10.6) cancer. Prevalence of preterm birth (8.9 vs. 8.0%, p = .02) and low birth weight (6.0 vs. 5.3%, p = .02) was higher for liveborn offspring of male AYAs compared to men without cancer. There was no difference in prevalence of birth defects (4.9 vs. 4.8%, p = .64). Conclusions Our findings underscore the continued importance of reproductive counseling for AYAs.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"116 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Intersectional Analysis of Behavioral Financial Hardship and Healthcare Utilization among LGBTQ+ Cancer Survivors LGBTQ+癌症幸存者的行为经济困难和医疗保健利用的交叉分析

Journal of the National Cancer Institute Pub Date : 2025-01-02 DOI: 10.1093/jnci/djae350

Austin R Waters, Stephanie B Wheeler, Jeremey Fine, Christabel K Cheung, Kelly R Tan, Donald L Rosenstein, Mya L Roberson, Erin E Kent

{"title":"An Intersectional Analysis of Behavioral Financial Hardship and Healthcare Utilization among LGBTQ+ Cancer Survivors","authors":"Austin R Waters, Stephanie B Wheeler, Jeremey Fine, Christabel K Cheung, Kelly R Tan, Donald L Rosenstein, Mya L Roberson, Erin E Kent","doi":"10.1093/jnci/djae350","DOIUrl":"https://doi.org/10.1093/jnci/djae350","url":null,"abstract":"Background lesbian, gay, bisexual, transgender, queer, or another non-heterosexual or cisgender identity (LGBTQ+) cancer survivors experience high financial hardship. However, structural drivers of inequities do not impact all LGBTQ+ individuals equally. Using All of Us data, we conducted an intersectional analysis of behavioral financial hardship among LGBTQ+ cancer survivors. Methods LGBTQ+ inequities in behavioral financial hardship (ie, cost-related foregone care, delayed care, and medication alterations) and non-cost-related delayed care were estimated using All of Us Data. Multivariable logit models were used to generate predicted probabilities, average marginal effects (AME), and 95% confidence intervals. Models were then used to estimate inequities when disaggregating LGBTQ+ status and combing LGBTQ+ status with age, race, ethnicity, and treatment status. Results This analysis included N = 36,217 cancer survivors (6.6%, n = 2,399 LGBTQ+). In multivariable models, LGBTQ+ identity was associated with higher probabilities of and significant AME for all types of behavioral financial hardship (foregone care 31.1% vs. 19.4%; delayed care 22.6% vs. 15.6%; medication alterations 19.2% vs. 11.9%) and non-cost delayed care (14.3% vs. 7.2%). Within the disaggregated analysis, cisgender bisexual and another/multiple orientation women and gender minority survivors had the highest predicted probabilities of all outcomes. In intersectional analyses, survivors who were aged 18-39 and LGBTQ+, Black and LGBTQ+, or Hispanic/Latine and LGBTQ+ had the highest predicted probabilities of all outcomes. Conclusions LGBTQ+ cancer survivors experience significantly more behavioral financial hardship and non-cost-related delayed care then non-LGBTQ+ cancer survivors. Interventions at the individual, system, and policy level are needed to address LGBTQ+ inequities in financial hardship.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142917832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Timing of depression in relation to risk of ovarian cancer 抑郁症与卵巢癌风险的时间关系

Journal of the National Cancer Institute Pub Date : 2025-01-02 DOI: 10.1093/jnci/djae348

Andrea L Roberts, Mary K Townsend, Lori B Chibnik, Laura D Kubzansky, Shelley S Tworoger

{"title":"Timing of depression in relation to risk of ovarian cancer","authors":"Andrea L Roberts, Mary K Townsend, Lori B Chibnik, Laura D Kubzansky, Shelley S Tworoger","doi":"10.1093/jnci/djae348","DOIUrl":"https://doi.org/10.1093/jnci/djae348","url":null,"abstract":"Objective Several studies have suggested that depression may be associated with increased risk of ovarian cancer. Less is known about whether timing matters regarding when depression occurs. To provide evidence for an etiologically relevant exposure period, we examined depression occurring during the time in which precursor lesions develop and progress to invasive carcinoma with risk of developing ovarian cancer. Methods Using data from two prospective cohorts (1992-2015), we divided follow-up into consecutive two-year periods for analytic purposes, referred to as “cancer ascertainment periods.” We estimated associations of depression in the 10 years before each cancer ascertainment period with incident cancer, using Cox proportional hazards models. Next, we estimated associations of depression occurring up to 18 years before each ascertainment period, in two-year increments, with incident cancer. We adjusted for demographic, health, and behavioral factors. All tests of statistical significance were 2-sided, with a p-value threshold of &lt; 0.05. Results Depression occurring in the 10 prior years was associated with 30% greater risk of cancer (hazard ratio (HR)=1.30, 95% confidence interval (CI)=1.15-1.46). Associations were similar in fully adjusted models (HR = 1.27). Depression occurring in the 14 years before ascertainment was associated with elevated risk, although only estimates for depression 0-2, 6-8, and 8-10 years before ascertainment reached statistical significance (HR range, 1.20-1.36). Conclusion Depression occurring up to 14 years before cancer ascertainment was associated with greater cancer risk. This is the time of precursor progression to invasive ovarian carcinoma, suggesting depression may be an ovarian cancer promoting agent.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142917407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Delta-Like Ligand 4-Notch Blockade and Tumor Radiation Response. 修正：δ样配体4-Notch阻断与肿瘤辐射反应。

Journal of the National Cancer Institute Pub Date : 2024-12-26 DOI: 10.1093/jnci/djae337

引用次数: 0

Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access 妇科癌症临床试验资格标准作为公平临床试验准入的标志

Journal of the National Cancer Institute Pub Date : 2024-12-19 DOI: 10.1093/jnci/djae338

Ann Oluloro, Elizabeth M Swisher, Heidi J Gray, Barbara Goff, Kemi M Doll

{"title":"Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access","authors":"Ann Oluloro, Elizabeth M Swisher, Heidi J Gray, Barbara Goff, Kemi M Doll","doi":"10.1093/jnci/djae338","DOIUrl":"https://doi.org/10.1093/jnci/djae338","url":null,"abstract":"Background Racial and ethnic minorities remain underrepresented in gynecologic cancer clinical trials despite disproportionately worse oncologic outcomes. Research shows differential racial enrollment patterns due to comorbidity-based exclusion criteria (CEC). Our objective was to evaluate contemporary trends in CECs among NCI-sponsored gynecologic cancer clinical trials and protocol adherence to broadened eligibility criteria guidelines as an assessment of equitable enrollment access. Methods The ClinicalTrials.gov registry was queried for NCI-sponsored gynecologic cancer clinical trials (1994-2021). Study characteristics and CECs were abstracted from protocols. Descriptive statistics and temporal trends were calculated using chi-square testing with STATA v17 software. Results Among 279 clinical trials identified, 65% completed enrollment, 53% were Phase II, and 48% focused on ovarian cancer. Pharmaceutical agents (85%) were the primary therapeutic interventions. Several inequitably restrictive exclusion criteria increased over time such as hepatitis infection (17% in 1994-2000 vs 49% in 2015-2021, p &lt; .001) and cardiovascular disease (47% in 1994-2000 vs 66% in 2015-2021, p = .002). A previously rare exclusion, “mental illness/social situations,” dramatically increased from 5% to 51% (p &lt; .001) over three decades. Adherence to broadened eligibility criteria recommendations was mixed. Renal function, cardiovascular disease, and performance status criteria were not broadened but HIV, prior/concurrent malignancies, and brain metastasis criteria were. Conclusions Some, but not all, of the known restrictive CECs have increased in gynecologic cancer clinical trial design, despite calls for improving racial and ethnic minority representation. While exclusion criteria are critical for trial safety, they must be carefully considered given the differential racial impact on eligibility.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"86 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142858417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women 美国男性和女性的饮酒模式和饮酒时间与结直肠癌风险的关系

Journal of the National Cancer Institute Pub Date : 2024-12-17 DOI: 10.1093/jnci/djae330

Xinyi Li, Jinhee Hur, Yin Zhang, Mingyang Song, Stephanie A Smith-Warner, Liming Liang, Kenneth J Mukamal, Eric B Rimm, Edward L Giovannucci

{"title":"Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women","authors":"Xinyi Li, Jinhee Hur, Yin Zhang, Mingyang Song, Stephanie A Smith-Warner, Liming Liang, Kenneth J Mukamal, Eric B Rimm, Edward L Giovannucci","doi":"10.1093/jnci/djae330","DOIUrl":"https://doi.org/10.1093/jnci/djae330","url":null,"abstract":"Background Association between light to moderate alcohol consumption and colorectal cancer (CRC) incidence remains understudied, especially regarding drinking pattern, beverage type and temporal aspects. Methods Hazard ratios (HRs) and 95% confidence intervals (CIs) for time to CRC diagnosis were estimated among 137,710 participants. Estimates based on remote (eg, &gt;10 years before follow-up) and recent (eg, the preceding 10 years before follow-up) alcohol intake, using different cutoffs (eg, 8, 10, 12 years, etc) and mutual adjustment, enabled separating independent effects and investigating time lag of alcohol-CRC association. Results 3,599 CRC cases were documented over three decades. Light to moderate drinking was associated with an increased CRC risk only in men: HR (95% CI) for 5-14.9 and 15-29.9 vs 0 g/day of alcohol intake was 1.19 (1.01, 1.41) and 1.38 (1.13, 1.67). In women, that for 0.1-4.9 and 5-14.9 vs 0 g/day of alcohol was 1.07 (0.96, 1.20) and 1.05 (0.91, 1.20). Drinkers with both high drinking frequency and daily intake had the highest CRC risk, suggesting total alcohol intake was the critical factor. We estimated the time lag between alcohol consumption and CRC occurrence to be 8 to 12 years. Former drinkers did not experience a significant reduction in CRC risk even after 10 years of quitting or reducing consumption. Conclusions Based on two cohorts of health professionals, our findings suggest that the increased risk of CRC associated with alcohol intake is mainly driven by total quantity and remote intake. Former drinkers did not experience an immediate reduction in CRC risk after quitting or reducing consumption.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142841556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TP53 missense allele predisposing to high risk of breast cancer but not pediatric cancers TP53错义等位基因易患乳腺癌，但不易患儿科癌症

Journal of the National Cancer Institute Pub Date : 2024-12-14 DOI: 10.1093/jnci/djae334

Suhair Lolas-Hamameh, Sari Lieberman, Alaa Sarahneh, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Grace Rabie, Rachel Beeri, Amal Aburayyan, Jessica B Mandell, Hila Fridman, Galit Lazer-Derbeko, Tehila Klopstock, Orit Freireich, Amnon Lahad, Mary-Claire King, Ephrat Levy-Lahad, Moien N Kanaan

{"title":"TP53 missense allele predisposing to high risk of breast cancer but not pediatric cancers","authors":"Suhair Lolas-Hamameh, Sari Lieberman, Alaa Sarahneh, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Grace Rabie, Rachel Beeri, Amal Aburayyan, Jessica B Mandell, Hila Fridman, Galit Lazer-Derbeko, Tehila Klopstock, Orit Freireich, Amnon Lahad, Mary-Claire King, Ephrat Levy-Lahad, Moien N Kanaan","doi":"10.1093/jnci/djae334","DOIUrl":"https://doi.org/10.1093/jnci/djae334","url":null,"abstract":"Pathogenic TP53 germline variants cause young-onset breast cancer and other cancers of the Li-Fraumeni syndrome (LFS) spectrum, but the clinical consequences of partial-loss-of function TP53 variants are incompletely understood. In the consecutive cohort of Palestinian breast cancer patients of the Middle East Breast Cancer Study (MEBCS), breast cancer risk among TP53 p. R181C heterozygotes was 50% by age 50 y and 81% by age 80 y. In contrast, prevalence of pediatric cancers in the MEBCS was similar among first degree relatives of TP53 p. R181C carriers (3/519 = 0.0058) and first degree relatives of MEBCS patients with no pathogenic germline variant in any known breast cancer gene (7/1082 = 0.0065; OR = 0.90, 95%CI [0.23,3.49], Fisher P = .90 (2-tailed)). This result suggests that in families harboring this TP53 allele, genetic testing in children is unwarranted, and screening children for LFS tumors is unnecessary. More generally, some TP53 missense alleles can predispose to very high risk of breast cancer without pleiotropic effects.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acceptability of an organ inventory for cancer screening across gender identity and intersex status 跨性别认同和双性人身份的癌症筛查器官清单的可接受性

Journal of the National Cancer Institute Pub Date : 2024-12-14 DOI: 10.1093/jnci/djae336

Heidi Moseson, Sachiko Ragosta, Anu Manchikanti Gómez, Jae Corman, Jay Zussman, Bori Lesser-Lee, Sydney Reese, India Rose Carter-Bolick, Juno Obedin-Maliver

{"title":"Acceptability of an organ inventory for cancer screening across gender identity and intersex status","authors":"Heidi Moseson, Sachiko Ragosta, Anu Manchikanti Gómez, Jae Corman, Jay Zussman, Bori Lesser-Lee, Sydney Reese, India Rose Carter-Bolick, Juno Obedin-Maliver","doi":"10.1093/jnci/djae336","DOIUrl":"https://doi.org/10.1093/jnci/djae336","url":null,"abstract":"Objectives To evaluate the acceptability and performance of an organ inventory as an alternative to asking about gender and/or sex assigned at birth in cancer screening. Methods We fielded an online, self-administered survey to a convenience sample of English- or Spanish-speaking transgender and gender-diverse (TGD), intersex, and cisgender people (&gt;/=15 years) in the US. The survey contained an organ inventory developed with community input and questions regarding acceptability. The primary outcome was organ inventory acceptability by the four-item Acceptability of Intervention Measure (AIM). Additional outcomes included inter-method screening agreement between the organ inventory, gender, and sex assigned at birth. Results In 2022, 333 eligible individuals completed the survey; 44.4% cisgender, 34.2% TGD, and 14.1% intersex. Overall, participants rated the organ inventory as acceptable (median AIM score = 18/20, IQR: 16-20). Most (73%) found it easy to understand, and comfortable to complete (65%). Cancer screening eligibility varied based on the method used; relying solely on gender or sex data would have missed some eligible participants that the organ inventory identified. Conclusions Using an organ inventory as an alternative to gender or sex-based screening questions was acceptable, and has implications for addressing cancer screening disparities.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"146 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Time-Restricted Eating and Cancer: Lessons Learned and Considerations for a Path Forward 限时饮食和癌症：经验教训和前进道路的考虑

Journal of the National Cancer Institute Pub Date : 2024-12-12 DOI: 10.1093/jnci/djae331

Marissa M Shams-White, Audrey A Goldbaum, Tanya Agurs-Collins, Susan Czajkowski, Kirsten A Herrick, Linda Nebeling, Jill Reedy, Gabriela Riscuta, Sharon Ross, Edward R Sauter

{"title":"Time-Restricted Eating and Cancer: Lessons Learned and Considerations for a Path Forward","authors":"Marissa M Shams-White, Audrey A Goldbaum, Tanya Agurs-Collins, Susan Czajkowski, Kirsten A Herrick, Linda Nebeling, Jill Reedy, Gabriela Riscuta, Sharon Ross, Edward R Sauter","doi":"10.1093/jnci/djae331","DOIUrl":"https://doi.org/10.1093/jnci/djae331","url":null,"abstract":"Time-restricted eating (TRE) is a type of intermittent fasting (IF). Food can be consumed as desired during the eating period, but not during the remainder of the day. Studies suggest that many of the health benefits of fasting may not simply be the result of weight loss, but also due to the body’s responses to the fasting that lead to improved metabolic functioning. While animal studies are convincing regarding the benefits of time restricted feeding, human (TRE) studies are less consistent and generally short term (&lt; 1 year). In 2020, the National Cancer Institute (NCI) funded five IF studies, four of which focused on TRE, which addressed the question “How does intermittent fasting affect cancer incidence, treatment response, or outcome?” NCI sponsored a webinar in 2023 featuring investigators of the funded studies in which they discussed challenges as well as their thoughts regarding the most important TRE topics that should be addressed going forward. Six areas were identified, which are discussed below as well as in a recently published NOT-CA-24-073: Factors impacting how Time-Restricted Eating (TRE) influences cancer-related outcomes. Moving the science forward will allow the scientific community to better understand TRE’s potential. This potential includes the development of targeted TRE interventions to optimize long-term adherence to the intervention, which is required to better understand fully explore its potential benefits in cancer risk, increased response to cancer treatment, as well as improved quality and quantity of life among cancer survivors.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"235 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing public private partnerships to support clinical cancer research 优化公私伙伴关系，支持临床癌症研究

Journal of the National Cancer Institute Pub Date : 2024-12-12 DOI: 10.1093/jnci/djae279

Roy S Herbst, Gideon Blumenthal, Samir N Khleif, Scott M Lippman, Neal J Meropol, Kristen Rosati, Lawrence N Shulman, Heind Smith, Meina Wang, Robert A Winn, Richard L Schilsky

{"title":"Optimizing public private partnerships to support clinical cancer research","authors":"Roy S Herbst, Gideon Blumenthal, Samir N Khleif, Scott M Lippman, Neal J Meropol, Kristen Rosati, Lawrence N Shulman, Heind Smith, Meina Wang, Robert A Winn, Richard L Schilsky","doi":"10.1093/jnci/djae279","DOIUrl":"https://doi.org/10.1093/jnci/djae279","url":null,"abstract":"Public-private partnerships (PPPs) in cancer research have emerged as a pivotal model in the development of strategies to rapidly advance therapeutic innovations. The collaboration between public entities, such as government agencies and research institutions, and private entities, including pharmaceutical and biotechnology companies, as well as nonprofit organizations, brings together diverse expertise, resources, and perspectives to address the challenges of efficient drug development and equitable care delivery. This synergy has the potential to accelerate the translation of basic research findings into tangible clinical applications. However, the implementation of PPPs is challenging and fraught with pitfalls that must be overcome if the PPP is to be successful in achieving its goals. To address these issues, in October 2023, the National Cancer Policy Forum and the Forum on Drug Discovery, Development, and Translation held the “Optimizing Public-Private Partnerships for Clinical Cancer Research” Workshop in Washington D.C. The goal of the workshop was to examine opportunities to promote collaboration among these various entities through public-private partnerships (PPP) to facilitate more timely and effective clinical cancer research. Key guiding principles and strategies were highlighted, and the challenges and barriers to implementing a PPP and recommendations to overcome those obstacles are summarized herein.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0